NDAORAL, RECTALSOLUTION
Approved
Jan 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GASTROGRAFIN (diatrizoate meglumine and diatrizoate sodium) by Bracco is clinical pharmacology the most important characteristic of contrast media is the iodine content. First approved in 1958.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GASTROGRAFIN is an oral and rectal radiographic contrast medium containing diatrizoate meglumine and diatrizoate sodium, used for gastrointestinal imaging of the esophagus, stomach, small intestine, and colon. The iodine content provides radiodensity for visualization, while the high osmolarity produces a mild laxative effect to facilitate bowel transit and opacification.
LOE Approaching
As a legacy diagnostic product approaching loss of exclusivity, the commercial footprint is likely contracting with minimal new team growth.
Mechanism of Action
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast with surrounding tissues. Diagnostic enteral radiopaque agents have few known pharmacological…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Worked on GASTROGRAFIN at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.